The nation of Zimbabwe has rejected a major American health deal worth 367 million US dollars (£272m) spanning five years over Washington's demand for confidential biological samples.
The decision came to light following a internal memorandum from December was disclosed, revealing that President Emmerson Mnangagwa deemed the deal was "unbalanced".
An official spokesperson later stated that the US was requesting genetic material for research and profit while refused to share the benefits from future vaccines.
"We will now turn to the difficult and regrettable task of scaling back our health assistance in Zimbabwe," stated US ambassador to Zimbabwe Pamela Tremont in a statement.
Her embassy said the US had furnished over $1.9bn for health programmes to Zimbabwe during the past two decades.
A medical body in Zimbabwe has called for further talks to reach a agreement acceptable to all parties so the nation's critical HIV treatment initiative can continue.
Broader Context
Zimbabwe's decision follows a comparable situation in neighbouring Kenya, where a high court halted a related health funding agreement following concerns were filed about the security of citizens' medical information.
After resuming office last year, US President Donald Trump has slashed foreign aid and shut down the US Agency for International Development (USAID).
The agency had administered assistance for the US government, but Trump claimed its spending was "wasteful" and his administration was seeking government-to-government deals to boost transparency and accountability.
According to reports, 16 nations in Africa have to date signed similar agreements, constituting over $18.3bn of fresh investment.
Specifics of the Rejected Deal
The funds for Zimbabwe was intended to funded "combating HIV/Aids, TB, malaria, maternal and child health, and preparing for epidemics".
"We believe this collaboration would have delivered significant advantages for the people of Zimbabwe, especially the 1.2 million men, women and children currently receiving HIV treatment via American-funded programmes," Tremont commented.
However, government spokesperson Nick Mangwana argued the arrangement was "unequal".
"Our nation was requested to share its biological resources and data for a long time, without any corresponding guarantee of access to any scientific breakthroughs – such as vaccines, diagnostics, or treatments – that might result from that provided information," Mangwana explained.
"In essence, our nation would provide the basic resources for scientific discovery with no certainty that the final treatments would be available to our population should a future disease outbreak emerge."
Sovereignty and International Frameworks
Mangwana further pointed out that the American exit from the global health body and its push of one-on-one health agreements were upending structures previously established via the international organization.
Mangwana gave as an example its Pathogen Access and Benefit Sharing system created to deal with future pandemics.
"This framework is intended to guarantee that when a nation provides its information, the resulting advantages – including vaccines and treatments – are shared equitably, not commercialised exclusively by those with the capability to create them."
The government's concerns over the US deal "are not meant as opposition to America," Mangwana stressed.
"We welcome ongoing dialogue with our US partners on how future co-operation might be structured in a way that respects the independence and interests of each country."
Medical Community Reaction
The Zimbabwe College of Public Health Physicians (ZCPHP) said it recognised the official position, but suggested that negotiations should continue since much of the country's Aids initiatives relied on external financing.
"If technical issues arise, including those relating to data governance or agreement terms, these can often be addressed through detailed discussion and negotiated safeguards," the group added.
The halted deal underscores the ongoing tensions between accepting crucial foreign assistance and protecting a country's data in an increasingly interconnected world.